The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer.
 
Christopher Jakubowski
Honoraria - OBR/Caribou Publishing
 
Natalie B Collins
No Relationships to Disclose
 
Elizabeth Ann Sugar
No Relationships to Disclose
 
Maureen Berg
No Relationships to Disclose
 
Haihui Cao
No Relationships to Disclose
 
Marios Giannakis
Honoraria - AstraZeneca
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - Patent pending on biomarkers of immune response
 
Elizabeth M. Jaffee
Consulting or Advisory Role - Adaptive Biotechnologies; CStone Pharmaceuticals; Dragonfly Therapeutics; Genocea Biosciences; Incyte
Research Funding - Aduro Biotech; Amgen; Bristol-Myers Squibb; Corvus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genocea Biosciences; MedImmune
Other Relationship - Dragonfly Therapeutics
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology; Taiho Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bayer; Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group; EMD Serono; Genentech (Inst); Incyte; Intensity Therapeutics (Inst); Merck (Inst); Syndax (Inst)